2011年5月23日,美国FDA批准特拉匹韦(telaprevir)用于成人慢性丙型肝炎的治疗。本品可用于未接受过干扰素类药物治疗或对之前的药物治疗无效的患者。特拉匹韦被批准与聚乙二醇干扰素α及利巴韦林联用。其最常见的不良反应是皮疹和贫血等。本文对特拉匹韦的药理作用、药代动力学、临床评价、适应症、用法用量和安全性等进行介绍。 May 23, 2011, the United States FDA approved telaprevir (telaprevir) for the treatment of chronic hepatitis C in adults. This product can be used for patients who have not received interferon treatment or previous drug treatment ineffective. Telaprevir is approved for use with peginterferon alfa and ribavirin. The most common adverse reactions are rashes and anemia. This article describes the pharmacological effects of telaprevir, pharmacokinetics, clinical evaluation, indications, usage dosage and safety.